ArticlePediatric pulmonology2025
Efficacy of Intravenous Methylprednisolone Pulses in Children With Postinfectious Bronchiolitis Obliterans.
Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo assess the efficacy of intravenous methylprednisolone pulses in children with postinfectious bronchiolitis obliterans (PIBO). STUDY DESIGN/
methodsThis French monocentric retrospective study included 31 patients with PIBO. Respiratory symptoms, occurrence of exacerbations and hospitalizations up to 4 years, and the results of lung function tests were compared between patients who received methylprednisolone pulses (n = 6) and those who did not (n = 25). A similar analysis was performed in the subgroup of the severest patients at diagnosis (five and six patients per group respectively).
resultsDuring their inaugural episode, patients in the treatment group were hospitalized longer (p = 0.005), more frequently in ICU (p = 0.013) and had longer oxygen needs than in the control group (p = 0.005). During their course, more patients in the treatment group required at least one nonscheduled hospitalization at 6 months of evolution than in the control group (p = 0.04). Regarding lung function tests, no significant difference was observed between the control and treatments groups. Comparing the severest patients at diagnosis in each group showed no significant difference in clinical nor functional evolution.
conclusionIn a retrospective monocentric cohort, intravenous methylprednisolone pulses were used in severe cases of PIBO. This treatment had no effect of the subsequent evolution of these patients as compared to not treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.